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Background: Merkel cell carcinoma is a rare and aggressive neoplasm originating from mechanoreceptor Merkel
cells of the stratum basale of the epidermis. Cases affecting the vulva are exceedingly rare, with the currently
available literature primarily in case report form.
Body: Systematic review of the PubMed database returned 17 cases of Merkel cell carcinoma affecting the vulva.
Patients presented at a mean age of 59.6 years with a firm, mobile vulvar mass. Symptoms of pain, erythema,
pruritus, edema, and ulceration have been reported. Tumor histology is consistent with that of neuroendocrine
tumors and typical Merkel cell carcinomas. Neuroendocrine and cytokeratin immunostains are frequently utilized in
histopathological workup. Surgical management was the unanimous first-line therapy with adjuvant radiation in
most cases. Recurrence occurred in 70.6% of patients at a mean follow-up of 6.3 months. Mortality was at 47.0% at
a mean of 7.8 months after initial operation.
Conclusion: Merkel cell carcinoma affecting the vulva is an extremely rare and highly aggressive neoplasm. The
present review of published cases serves to comprehensively describe the clinical course and treatment approaches
for vulvar Merkel cell carcinoma.
Keywords: Vulvar neoplasms, Skin neoplasms, Merkel tumor, Neuroendocrine tumorsBackground
Merkel cell carcinoma (MCC) is a rare and aggressive
neoplasm first described in 1972 by Toker [1]. The
tumor is thought to originate from the Merkel cell
mechanoreceptors located in the stratum basale of the
epidermis [2]. Although rare, the incidence of this neo-
plasm is increasing due to the advancing age of the
population, higher rates of sun exposure, and a growing
proportion of immunocompromised individuals [2].
MCC occurs predominately in the elderly with an average
age of onset at 69 years old and a slightly higher preva-
lence in males (1.56:1 Male:Female) [3]. Additional risk
factors include Caucasian race (incidence of 0.23 per
100,000) [2] and immunosuppression, with a younger age
at presentation for immunocompromised individuals [4].
The neoplasm is predominately found in the head and
neck (41–50%), followed by the extremities (32–38%), and
then the trunk (12–14%) [2]. Regarding the etiology of the* Correspondence: AHN30605@creighton.edu
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tected in 43 to 100% of MCC tissue samples. The
pathogenesis of this Merkel cell polyomavirus, however,
still requires further investigation.
The primary lesion of MCC typically presents as a
solitary, painless, rapidly growing, red to bluish nodule
[2, 6]. Definitive diagnosis requires histopathologic ana-
lysis of a biopsy. Upon hematoxylin and eosin staining,
the lesion will appear similar to other neuroendocrine
tumors consisting of small round cells, hyperchromic
nuclei, frequent mitosis, and variable architecture [2].
With hematoxylin and eosin staining alone it is difficult
to differentiate MCC from other small cell tumors, espe-
cially metastatic small cell cancer of the lung. Accord-
ingly, immunohistochemical evaluation is recommended
[2, 7]. An immunopanel including cytokeratin 20 (CK20)
and thyroid transcription factor-1 (TTF-1) allows the
greatest sensitivity and specificity for excluding small cell
lung cancer [7]. CK20 is highly sensitive for MCC (posi-
tive in 89 to 100% of cases) while TTF-1 is sensitive for
small cell lung cancer (positive in 83 to 100% of cases),
and consistently negative in MCC [7].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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Fig. 1 Initial PubMed search returned 146 studies. Screening by title
and abstract left 18 studies, of which full text was reviewed.
Ultimately, 17 cases were included in this review
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historically, the most recent and widely accepted staging
guideline is the AJCC staging system [7, 8], which draws
upon evidence from the analysis of 5823 cases in the
National Cancer Database with a median follow-up of
64 months [3, 7]. Staging affects an individual’s progno-
sis, with 5-year survivals rates of 79% at stage IA to only
18% at stage IV [3]. Additionally, 50 to 70% of patients
will develop lymph node metastases and 33 to 70% of
those will go on to develop distant disease [2]. The most
common sites of metastasis are as follows: brain (18%),
liver (13%), lung (10–23%), bone (10–15%), distant skin
(9–30%), and distant lymph node (9%) [2]. Due to this
high rate of metastasis, patients with a primary MCC
should be screened for nodal metastases with sentinel
lymph node biopsy. Additionally, other imaging modal-
ities are gaining importance during diagnostic workup.
For example, PET/CT may be useful in identifying dis-
tant metastases [7]. In one article reviewing 102 patients,
PET/CT altered the stage and treatment course in 22%
of the cases [9].
Treatment of MCC varies by stage, with the main cat-
egories being treatment of the primary lesion, treatment
of regional disease, and treatment of distant metastasis.
Surgical excision is the treatment of choice for primary
lesions [2, 6, 7]. The two surgical approaches are wide
local excision with 1 to 2 cm margins and depth to the
investing fascia or Mohs surgery. These approaches have
equal efficacy if they attain tumor-free margins [2]. In
addition to surgery, adjuvant radiotherapy is often rec-
ommended. Postoperative radiation has shown to lower
the risk of local and regional recurrences and has been
associated with a longer overall survival [7]. In the case
of a positive node, adjuvant therapy to the nodal basin is
recommended and associated with longer disease-free
survival [2, 6]. Adjuvant therapy often consists of surgi-
cal removal of the basin nodes or regional radiotherapy,
or a combination of the two. It is recommended to get a
multidisciplinary tumor board consultation in metastatic
disease, and to consider any combination of additional
surgery, radiotherapy, and chemotherapy [7]. Recommen-
dations concerning follow up for patients after MCC treat-
ment are broad [7]. This allows for individualization based
on patient factors and physician preference. The standard
regimen is routine physical and skin exam every 3 to
6 months for the first 2 years, followed by every 6 to
12 months thereafter. This recommendation takes into
consideration that the median time to recurrence is
8 months with 90% of recurrences happening within
2 years [7].
While MCC is rare, a primary lesion affecting the
vulva is extremely rare. The vulvar location of primary
tumors is especially unique as cutaneous MCC is charac-
teristically more frequent in men [3]. A study of 3870MCC cases from the National Cancer Institute’s Surveil-
lance, Epidemiology, and End Results Program database
found only two cases (0.05%) affecting the vulva [10].
Currently, all data on vulvar MCC is found in “case re-
port and literature review” form. The present study
seeks to comprehensively review the available patient
data to accurately describe the clinical course and treat-
ment approaches for vulvar MCC.Main text
Search strategy
The National Library of Medicine’s PubMed database
was systematically searched to December 2016 without
date restrictions using the following search terms: “vulva”
and “vulvar” combined with “Merkel cell carcinoma,” “cuta-
neous apudoma,” “neuroendocrine carcinoma,” “trabecular
carcinoma.” Titles and abstracts were screened for possible
inclusion, followed by full text of potentially relevant stud-
ies. Included studies were original studies discussing the
clinical course (including presentation, diagnostic workup,
treatment, and outcome) of patients with MCC affecting
the vulva. Studies were excluded if not written in English,
not of primary human subjects, or not malignancies of the
vulva.
Initial PubMed search (see Fig. 1) returned 146 poten-
tially relevant articles. After screening of titles and ab-
stracts, the full text of 18 studies was retrieved for review
[11–27]. Upon full text review, one study was excluded for
providing insufficient clinical data on patient-level clinical
course (i.e. this study was a large cancer database study of
general MCC with minimal summary statistics provided
specifically for vulvar MCC). Ultimately, 17 case reports
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were reported in the United States (7 cases), followed by
Spain (2 cases).Table 2 Histopathological evaluation of vulvar merkel cell
carcinomas
Characteristic n (%)
Histologic finding (n = 17)
Small cells 12 (70.6)
High N/C ratio, scant cytoplasm 12 (70.6)
Nests, islands, trabecular 11 (64.7)
Hyperchromatic 10 (58.8)
High mitotic index 8 (47.1)
Necrosis 6 (35.3)
Irregular nuclei 4 (23.5)
Fibrous 4 (23.5)
Apoptosis 4 (23.5)Clinical presentation
Patients presented at a mean age of 59.6 years (range
28–79 years). The clinical presentation of the 17 included
cases are summarized in Table 1. Lesions were most com-
monly located on the labia majora (n = 9, 52.9%) with no
distinct predilection for side (left, n = 9; right: n = 7; unre-
ported: n = 1). 23.5% of cases (n = 4) extended to affect the
vaginal wall, while other affected anatomical locations in-
cluded the labia minora, paraclitoral or the bartholin gland.
Patients generally complained of a rapidly growing mass
(average history of 4.7 months, range of 1–18 months) that
was 7.5 cm (range 1.75–47.5 cm) on average at presenta-
tion. The lesions was described as a firm, painless (n = 3,
17.6%) or tender (n = 5, 29.4%) nodule that was mobile.
Cases reported associated pruritus (n = 2, 11.8%), swelling
or edema (n = 3, 17.6%), ulceration (n = 4, 23.5%), and
erythema (n = 2, 11.8%). Bleeding and purulent dis-
charge was reported in a fraction of cases (each, n = 2,
11.8%). Discoloration (n = 3, 17.6%) was reported as
yellow, purple or brown.Table 1 Clinical presentation of vulvar merkel cell carcinoma
(n = 17)
Characteristic n (% or range)
Mean age (years) 59.6 (28–79)
Mean tumor diameter (cm) 7.5 (1.8–47.5)
Mean disease duration (months) 4.7 (1–18)
Locationa
Labia majora 9 (52.9)
Labia minora 3 (17.6)
Paraclitoral 1 (5.9)
Bartholin gland 3 (17.6)
Intravaginal extension 4 (23.5)
Inguinal 1 (5.9)










aSum exceeds 100% due to non-mutually exclusive categoriesWorkup
Blood and urine chemistries were unremarkable in the
few cases reporting values, excepting occasional comor-
bidities that did not impact vulvar MCC diagnostics.
Histopathological evaluation (Table 2) was the primary
diagnostic modality, performed using needle biopsy (n =
5, 29.4%), incisional or excisional biopsy (n = 5, 29.4%),
evaluation following tumor resection (n = 1, 5.9%), or
unspecified (n = 6, 35.3%). Histologically, vulvar MCC isSheets 3 (17.6)
Hemorrhage 2 (11.8)
Ulceration 2 (11.8)
Electron microscopy (n = 7)a
Dense core granules 6 (85.7)
Intermediate filaments 5 (71.4)





PGP 9.5 2 (14.3)
Keratin stains (n = 13)a
Pancytokeratin AE1/AE3 7 (53.8)
CAM5.2 4 (30.8)






Perinuclear dot/granular 7 (53.8)
Abbreviations: CK cytokeratin, N/C ratio nuclear/cytoplasmic ratio, NSE neuron
specific enolase, PGP protein gene product
aTotal n, reflected in percentages, is less than 17 due to inconsistent reporting
of electron microscopy or positive and negative immunostains
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(see Fig. 2). Routine evaluation with hematoxylin and
eosin demonstrated small, undifferentiated, hyperchro-
matic cells with a high N/C ratio and scanty cytoplasm.
Cells were arranged in nested, trabecular pattern (n = 11,
64.7%) separated by fibrous connective bands and/or
were in sheets (n = 3, 17.6%). Indicators of aggressive
malignancy were common, including high mitotic index
(n = 8, 47.1%), irregular nuclei (n = 4, 23.5%), necrotic and
apoptotic cells (n = 6 and 4, respectively), hemorrhage
(n = 2, 11.8%) and ulcerated dermis (n = 2, 11.8%). Electron
microscopy was reported in 7 cases (41.2%). In these cases,
tumor cells exhibited cytoplasmic membrane-bound dense
core neurosecretory granules (n = 6, 85,7%) and intermedi-
ate filaments (N = 5, 71.4%).
Immunostain results were reported in all but 2 cases
and are summarized in Table 2. Neuroendocrine and
keratin stains were the most commonly used for histo-
pathological diagnostic workup. Cases commonly stained
positive for neuron specific enolase (n = 7), chromogranin
(n = 7), and synaptophysin (n = 6). Keratin stains included
pancytokeratin AE1/AE3 (n = 7), CAM5.2 (n = 4), and lowFig. 2 Photomicrographs of a typical Merkel cell carcinoma at a 4x, b 40x,
small, undifferentiated cells with high N/C ratio and scanty cytoplasm. Typi
AE1/AE3 (100x oil immersion), f CK 20 (100x oil immersion), and neuroendomolecular weight cytokeratins (n = 3). Generally, cytokera-
tin immunoreactivity patterns demonstrated perinuclear
dots and/or cytoplasmic granularity. Other immunostains
with two or fewer positives included CD56, Ki-67, endo-
mysial antibody, carcinoembryonic antigen, and S100.
Stains with no positives included CD45, TTF-1, HMB45,
desmin, vimentin, smooth muscle actin, CA125, CD31,
and CD34.
Ultrasound was performed in 4 cases. While three re-
ports demonstrated no tumor findings on ultrasound,
one case [11] reported ultrasound to detect a well cir-
cumscribed, heterogeneous, cystic mass with irregular
vascularity. Plain chest radiographs were unremarkable
in all 9 cases reporting use of X-ray imaging, except one
case [20] in which extensive lung metastases were
shown. CT scans, performed in 10 cases, appeared to be
the most sensitive for detection of metastases.
Management and outcome
All patients received surgical excision as first line ther-
apy. Vulvectomy was performed in ten patients (58.8%).
Wide local excision was performed in 4 cases (23.5%)and c–d 100x objectives. Hematoxylin and eosin staining demonstrates
cal immunopanel demonstrates positive staining with e cytokeratin
crine markers such as g chromogranin (100x oil immersion)
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to be completed in one case due to inaccessibility of
the lesion, and surgical approach was not reported in
another case until recurrence. Inguinal lymph node dis-
section was reported in 10 cases (58.8%). Some form of
adjuvant radiotherapy was administered in 11 cases
(64.7%). Of those reporting sufficient data, radiation
dosage was 400 to 6500 cGy at first dose of adjuvant
radiotherapy, with additional courses at varied doses.
Radiation was administered locally in the pelvic region,
with some cases administering radiation at inguinal or
even para-aortic lymph nodes. 11 cases reported radi-
ation as a part of the treatment regimen, however
three did not provide follow-up results for the patient,
as radiotherapy had not been performed at the time
the cases were written [11, 12, 15]. Of the eight patients
with reported follow up, six patients experienced re-
currence at an average of 5.8 months after treatment
[14, 17, 21, 24–26]. Five of these cases reported the
amount of radiation therapy, with an average of 6008 cGy
[14, 21, 24–26]. Six patients had recurrent disease after
radiation therapy, three died after 0 [14], 3 [25], and
4 months [26] post-radiotherapy. Three patients with re-
currence were still alive at 0 [24], 0 [21], and 8 months
[17] post-radiotherapy. Of the two patients who did not
experience recurrence, one patient received 5940 cGy and
died at 8 months post-radiotherapy due to sepsis [18],
while the other received 5000 cGy plus an additional
5000 cGy targeted at original mass location and was still
alive at 24 months post-radiotherapy [16].
Patient prognosis was poor. Recurrence occurred in 11
patients (64.7%) at a mean follow-up of 4.7 months
(range 2–9 months). Two patients were disease-free at
13 and 24 months follow-up, respectively (three patients
lost to follow-up or outcome not reported). Recurrent
lesions were managed surgically or with cisplatin and
etoposide combination chemotherapy (n = 5; 2 cases did
not specify regimen). Eight patients (47.0%) succumbed
to advanced disease, with death at an average of 9.6 months
after initial surgical operation (range 0.36–20 months post-
operation). The clinical course of all included cases is sum-
marized in Table 3.
Discussion
The overall histopathological picture of vulvar MCC is
fairly consistent with typical MCC. Histological evalu-
ation remains the primary diagnostic modality, including
a hematoxylin and eosin section along with an appro-
priate immunopanel. National Comprehensive Cancer
Network guidelines for general MCC [7] recommend
immunopanels to include CK20 and TTF-1. Most low-
molecular-weight cytokeratin markers and CK20 will
be positive in a perinuclear dot-like pattern, while CK7
and TTF-1 (immunoreactive in >80% of small cell lungcancers) are typically negative [7]. Neuroendocrine
markers are recommended in only equivocal cases. Of the
presently reviewed vulvar MCC cases, 76.5% (n = 13) of
cases were evaluated using neuroendocrine markers, with
NSE as the most commonly used (n = 7). While 76.5%
(n = 13) of cases also included some sort of cytokeratin
staining, only five cases were stained for CK20 and two
cases were stained for CK7 (with 80% and 50% of cases
positive, respectively). Histopathological workup of vulvar
MCC appears to consistently include both neuroendocrine
and cytokeratin markers.
A study histopathologically evaluating 21 cases [28]
demonstrated MCC to express B cell lineage markers,
including terminal deoxynucleotidyl transferase (TdT)
and the paired box gene 5 (PAX 5). Additionally, most
of the MCCs evaluated in this study expressed one or
more immunoglobulin subclasses as well as kappa or
lambda chains. The TdT and PAX5 coexpression is sug-
gestive of a pro/pre- or pre-B cell origin for MCC, rather
than postmitotic Merkel cells in select tumors. This dis-
parity may aid in understanding why Merkel cell polyoma
viral infection is not present in all cases. Additionally, this
may have implications for therapy. Subclassification of
MCC tumors by immunophenotype could create a para-
digm of individualized treatment dictated by cellular origin
(i.e. pre-B cell-derived tumors versus postmitotic Merkel
cell tumors). However, further investigation is required
to substantiate this model of MCC origin. Additionally,
extensive clinical trials would be required to validate
treatment regimens based on origin.
Surgical excision is the first line approach to primary
MCC tumors. All reports received vulvectomy or wide
local excision with 2 cm margins. National Comprehen-
sive Cancer Network guidelines for general MCC [7]
recommend sentinel lymph node biopsy followed by sur-
gical removal using wide excision with 1–2 cm margins.
Removal to investing fascia of muscle or pericranium is
recommended, when clinically feasible. Additionally,
physicians may consider techniques that allow more ex-
haustive histologic margin assessment, such as Mohs
technique, modified Mohs with permanent sections for
final margin assessment, or complete circumferential
and peripheral deep margin assessment. No cases of vul-
var MCC reported more exhaustive margin assessment
such as Mohs techniques. Considering the high recur-
rence rate and the limits in accessibility for excision of
vulvar MCC, Mohs techniques could be of potential
value in the management of this condition. Such technique
could improve margin control and possibly increase tissue
preservation. A multi-institutional retrospective study [29]
of 240 MCC cases not limited by anatomic location re-
ported use of Mohs micrographic surgery in 13.8% of
patients, most commonly with stage I disease. While
overall survival of stage I/II patients did not differ with
Table 3 Summary of Clinical Presentation, Treatment, and Outcome of Vulvar Merkel Cell Carcinoma Cases
Case Age Location/Size Presentation Treatment Outcome + Survival
Bottles et al.
1984 [27]
73 Left labia majora. Minute ulcer w/chronic ulceration Initial: Testosterone + hydrocortisone
cream to heal initial ulcer.
10 months, 3 weeks: Vulvectomy +
Left Inguinal lymphadenectomy
9 Months: Local raised,
nodular, erythematous tumor
3 x 2 cm + Left Inguinal LN
metastases
11 months (11 days post
operation): death due to acute
MI + cardiopulmonary failure.
Inguinal and paraaortic nodes,
bone, liver, pulmonary vessel
metastases.
Copeland
et al. 1985 [26]
59 Left labium majus
6 x 8 cm
18 month history of painful
lump + Local tumor + Left Inguinal
LN metastases
Initial: Left hemivulvectomy +
lymphadenectomy + Radiotherapy
8 months: Vulvar lesion excision.




et al. 1988 [25]
47 Right labium
majus + vaginal
introit. 4.2 x 3 cm
3 month history of right labial/groin
swelling with brown vaginal
discharge and pain on sitting.
Local tumor + bilateral inguinal
LN metastases
Initial: Vulvectomy + Bilateral
lymphadenectomy + Radiotherapy
3 months: Excision + Chemotherapy
3 months: right thigh nodule,
forehead nodule, single
nodular lesion in left hilar
region.
6 months: Death. Autopsy:
hilar, lung, liver, pancreas
metastases.
Chandeying
et al. 1989 [24]
28 Right labium
majus 4 cm
1 month history of painless lump.
Local tumor + bilateral inguinal
LN metastases
Initial: Vulvectomy + bilateral
lymphadenectomy + radiotherapy
3 months: Right leg pain
improved with symptomatic
treatment.
4 months out: Alive. No
subsequent follow up.
Loret de Mola
et al. 1993 [23]
28 Left fourchette
1.5 x 2 cm
3 month history of Vulvar growth
and irritation. Local tumor
Initial: local excision.
2 months: Wide local excision + left
inguinal lymphadenectomy
8 months: chemotherapy





3 x 2.5 cm




9 months: bilateral Inguinal LN
and liver metastases.
10 months = Vulva, scalp, bone




68 Left labium minus
+ fourchette
4 x 3 cm.
5 month history of painless lump
with rapid growth in last 2 weeks.
Local tumor + overlying discolored
purplish skin. bilateral inguinal LN
metastases
Initial: Vulvectomy + bilateral inguinal
and Left pelvic Lymphadenectomy
2 months: Radiotherapy
Residual pelvic nodes post
treatment.
2 months: para aortic LN.
5 months: Alive with residual
disease.




3–4 month history of local tumor Initial: Wide Local excision 13 months: free of disease
Fawzi et al.
1997 [20]
78 Right vulvar mass
5.5 x 4 cm
1 month history of perineal itching
and discomfort. Pulmonary LN
metastases.
Initial: Radical vulvectomy + bilateral
inguinal LN dissection
20 days postoperative: break
down of right groin site and




79 Left labium minus
2.5 cm
Local tumor Initial: local excision.
2 months: Radiotherapy





62 Right labia majora
20 mm
Local painful tumor. Initial: local excision.
3 months: Radical vulvectomy +
Radiotherapy.
3 months: bilateral inguinal LN
metastases.
11 months: abdominal and
mediastinal LN.





49 Right vulvar mass
2 cm
Spontaneously ruptured Bartholin’s
gland abscess with small induration
at the site.
Initial: Drained abscess + wide local
excision + bilateral LN dissection +
Radiation therapy




35 Left labium majus
4 x 6 cm
One week history of painful
swelling of the vulva + purulent
discharge + LN mass
Initial: Drained abscess + antibiotics
+ partial excision
No follow up, patient planned
to receive radiotherapy in her
home country.
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Table 3 Summary of Clinical Presentation, Treatment, and Outcome of Vulvar Merkel Cell Carcinoma Cases (Continued)
Mohit et al.
2009 [14]
50 Left labia majora
3–4 cm
3 month history of palpable mass. Initial: local excision
2 months: Radiotherapy
2 months, 3 weeks: radical
vulvectomy
9 months: Chemotherapy
2 months: Recurrent mass
10 x 12 cm w/spontaneously
bleeding ulcerations
9 months: left hip pain
10 months: no evidence of
metastases
11 months: death due to
Pulmonary embolism




majus 5 x 7 cm
Post menopausal bleeding with
fungating primary lesion.
Initial: wide local excision. 2 months: local + distant
recurrence with multiple firm
inguinal LN bilaterally + death
before follow up treatment
Iavazzo et al.
2011 [12]
63 Left Labium 9 cm 6 month history of pruritus
treated w/corticosteroid cream.
5 cm inguinal LN metastases.







Patient noted Inguinal lesion. Initial: Surgical excision
Future plans for adjuvant
chemotherapy + radiotherapy
No follow up
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tissue preservation in these cohorts were not compared.
Further evaluation of the utility of Mohs technique in vul-
var MCC is warranted.
The high recurrence rate of MCC in spite of the em-
phasis on wide local excision and margin clearance
suggests surgical management of this condition to be
inadequate. In light of this poor clinical response to
surgical excision, further development of medical therap-
ies is paramount. Medical management in the available
published cases was limited to cisplatin and etoposide
combination therapy. With current medical management
consisting only of cytotoxic chemotherapy and radiation
(which causes many adverse side effects and is not
mechanism-based, disease-specific therapy) there is a need
for more effective and targeted treatment agents. Newer
developed agents, such as TKI’s, show encouraging effi-
cacy in other cancers and in some case reports when used
for MCC. Additionally they have low toxicity and lack im-
mune suppression due to the nature of their targeting ab-
errantly expressed genes commonly mutated in human
cancers. A case report of metastatic MCC in a 69-year-old
female demonstrated partial response to pazopanib, a
tyrosine kinase inhibitor (TKI) [30]. Multiple clinical trials
are underway investigating the efficacy of TKIs in MCC.
These include MLN0128 (mTOR, NCT02514824), cabo-
zantinib (c-Met and VEGFR2, NCT02036476), imatinib
(NCT00068783), temsirolimus (mTOR, NCT01155258),
and everolimus and vatalnib combination therapy
(NCT00655655). Other biologicals are also under investiga-
tion for treatment of patients with MCC, including adjuvant
ipilimumab (NCT02196961), avelumab (NCT02155647),
tremelimumab and durvalumab combination therapy
(NCT02643303). The age of biological and targeted
therapy is rapidly changing clinical oncology, as awhole, and is promising for treatment of advanced
MCC.Conclusion
Merkel cell carcinoma affecting the vulva is a rare and
aggressive neoplasm that presents as a firm, mobile mass
at a mean age of 59.6 years. Pain, ulceration, edema,
and erythema may also be present. The lesion is histo-
pathologically consistent with MCC, appearing as small
hyperchromatic cells with high nucleus to cytoplasm
ratio distributed in nested, trabecular patterns. Electron
microscopy demonstrates cells with dense core granules
and intermediate filaments. Neuroendocrine immunostain
markers aid in histopathological evaluation, especially
chromogranin, synaptophysin, and neuron-specific eno-
lase. Additionally, cytokeratin stains are commonly immu-
noreactive, including pancytokeratin stains and CAM5.2,
which will generally demonstrate a perinuclear dot or
cytoplasmic granularity. Surgical management is the pri-
mary treatment modality, and adjuvant radiotherapy may
be considered. However, recurrence and tumor progression
are very common problems. Metastatic disease may be
managed with cisplatin and etoposide combination therapy.
This condition has high mortality (47.0% of 17 cases) at a
mean follow-up of 7.8 months (range, 0.6–16 months) after
first surgical operation. Continued investigation of targeted
therapy is warranted for improved treatment in this highly
aggressive disease.
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